About
ImmunoIVD AB is a Swedish biotechnology company based in Stockholm, founded in 2015. The company specializes in developing and distributing innovative in vitro diagnostic (IVD) assays for newborn screening of rare immune and genetic disorders. Their mission is to provide sensitive and reliable screening solutions that enable early detection of life-threatening conditions in newborns, improving health outcomes through timely interventions. The company focuses on screening for severe combined immunodeficiency (SCID), X-linked agammaglobulinemia (XLA), and spinal muscular atrophy (SMA). Their flagship products include the CE-IVD marked SPOT-it™ Screening Kits, which utilize qPCR technology for efficient and cost-effective testing. These kits are designed for routine newborn screening laboratories and deliver results within approximately three hours from dried blood spot samples. ImmunoIVD collaborates closely with national and regional newborn screening laboratories, healthcare providers, and public health authorities to enhance screening programs across Europe. ImmunoIVD is also committed to environmental sustainability and actively participates in industry events to promote their products and foster new partnerships.
Technologies
Keywords
Company Information
-
Employees 30
-
Founded 2015
Location
3 Augustendalstorget, Stockholms laen, Sweden, 131 52
